$BCRX IMO this is why the BCRX PDUFA is different from other smallcap biotech PDUFA's: BCRX already has a HAE experienced sales team hired, trained & contacting future customers. Immediate sales following approval will quickly support the share price & The Sales Are "Pandemic Proof"... BCRX will be printing $$$ in December with Orladeyo approval. "We Are Ready To Launch The Day Orladeyo Is Approved" "50% of patients in the Berotralstat/Orladeyo long term safety study are switching from Takhzyro & Haegarda to Orladeyo" Estimate about 150-200 initial patients from Day 1 post approval. Assuming likely Bero/Orladeyo approval with Dec 3 PDUFA (or sooner...) if we use the lower $500,000 price per patient per year estimate about $42,000 per month per patient. If 200 initial patients BCRX will start off with a minimum of $8,400,000 monthly revenue in December/January & build from there. Perhaps $100,000,000+ annual sales "guaranteed" from Day 1. clinicaltrials.gov/ct2/show...
  • 37
37 Likes